Clinical trials: Renal Tumors
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic special pathological subtypes of renal cell carcinoma…
- Conditions
- Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05808608
- Testing
- AK104, Axitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Hao Zeng
Kidney Cancer, Renal Neoplasms
Tumor Rupture During Robotic Partial Nephrectomy
The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors.
- Trial name
- RUPTURE (NCT07065825)
- Testing
- robot-assisted partial nephrectomy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Renal Cell Carcinoma
Anesthesia and Cancer Study: Renal Cell Carcinoma
This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy.
- Trial name
- NCT04503148
- Testing
- Propofol, Inhaled General Anesthetics
- Where
- South Korea
- Volunteers
- 562 people
- Sponsor
- Seoul National University Hospital
Malignant Pleural Mesothelioma
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into…
- Trial name
- Immuno-MESODEC (NCT05765084)
- Testing
- Dendritic cell vaccination, Atezolizumab, Platinum/pemetrexed based chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Antwerp
High Grade Urothelial Carcinoma, Bladder Cancer
Renal Retention in High Grade Upper Tract Urothelial Cancer
This trial will evaluate the use of combination pembrolizumab and enfortumab vedotin for patients with high grade non-metastatic (cN0/NxMx, no measurable regional lymph nodes, no metastases) upper tract urothelial cancer (UTUC)…
- Conditions
- High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- NCT05656235
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long…
- Trial name
- NCT03538717
- Where
- 40 sites in Spain
- Volunteers
- 157 people
- Sponsor
- Pfizer
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer, Kidney Cancer
Preop Laxatives in Robotic Urologic Surgery
Minimally-invasive surgery, either laparoscopic or robotic, is commonly used in urology. Several urologic procedures including prostatectomy, radical nephrectomy, and partial nephrectomy are now commonly performed robotically.
- Conditions
- Prostate Cancer, Kidney Cancer, Constipation
- Trial name
- NCT05805436
- Testing
- Polyethylene Glycol 3350
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Chad R. Tracy
Bladder Cancer, Cervical Cancer
Zinc Supplements in Lowering Cadmium Levels in Smokers
RATIONALE: Zinc supplements may lower cadmium levels in smokers and may help prevent DNA damage. PURPOSE: This clinical trial is studying how well zinc supplements work in lowering cadmium levels in smokers.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00376987
- Testing
- zinc oxide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
The researchers are doing this study to find out whether the combination of abemaciclib and cabozantinib is a safe and effective treatment for people with metastatic clear cell renal cell carcinoma (ccRCC) and…
- Trial name
- NCT06835972
- Testing
- Abemaciclib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue
- Trial name
- NCT03793166
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib
- Where
- 859 sites in United States, Puerto Rico
- Volunteers
- 1,175 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Preference, Patient, Pharmacist-Patient Relations
Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital
To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to…
- Conditions
- Preference, Patient, Pharmacist-Patient Relations, Caregiver, Cancer
- Trial name
- IMPLICATION (NCT05970471)
- Where
- France
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Cell Carcinoma (RCC), Renal Cyst
The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy
The investigators combine radiomics and deep learning to analyze the lesions more thoroughly, aiming for a more accurate prediction of complications in partial nephrectomy, and compare this approach with traditional models.
- Trial name
- NCT06876584
- Where
- China
- Volunteers
- 1,474 people
- Sponsor
- Du Lingzhi
Renal Tumor
A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy
The multimodal analgesia for postoperative pain aims for optimal analgesia through additive or synergic drug effects. The multimodal analgesia results in the use of smaller doses of opioids and lowering opioid-related side…
- Trial name
- NCT01833728
- Testing
- nefopam-propacetamol combination, propacetamol alone
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Yonsei University
Metastatic Renal Cell Carcinoma
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor…
- Trial name
- NCT01152801
- Testing
- Everolimus (RAD001)
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Trial name
- NCT01672775
- Testing
- AGS-16C3F
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Agensys, Inc.
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.